Geode Capital Management, LLC Halozyme Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,027,384 shares of HALO stock, worth $157 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,027,384

Previous 2,919,763 3.69%

Holding current value

$157 Million

Previous $108 Million 14.12%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $3.62 Million - $4.51 Million	107,621 Added 3.69%	3,027,384 $123 Million
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $4.41 Million - $5.57 Million	132,414 Added 4.75%	2,919,763 $108 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $2.08 Million - $2.51 Million	57,081 Added 2.09%	2,787,349 $106 Million
Q2 2023 Aug 11, 2023	BUY	$30.28 - $38.74 $2.99 Million - $3.83 Million	98,881 Added 3.76%	2,730,268 $98.5 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $3.82 Million - $6.48 Million	116,290 Added 4.62%	2,631,387 $100 Million

Q4 2022 Feb 13, 2023	BUY	$40.06 - $59.44 $1.53 Million - $2.27 Million	38,233 Added 1.54%	2,515,097 $143 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $1.32 Million - $1.77 Million	34,166 Added 1.4%	2,476,864 $97.9 Million
Q2 2022 Aug 12, 2022	SELL	$37.35 - $48.3 $2.38 Million - $3.08 Million	-63,836 Reduced 2.55%	2,442,698 $107 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $1.02 Million - $1.31 Million	31,968 Added 1.29%	2,506,534 $100 Million
Q4 2021 Feb 11, 2022	BUY	$31.82 - $40.75 $496,169 - $635,414	15,593 Added 0.63%	2,474,566 $99.5 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $475,142 - $573,333	12,351 Added 0.5%	2,458,973 $100 Million
Q2 2021 Aug 13, 2021	BUY	$38.84 - $51.31 $6.97 Million - $9.2 Million	179,364 Added 7.91%	2,446,622 $111 Million
Q1 2021 May 12, 2021	BUY	$39.51 - $51.45 $5.51 Million - $7.18 Million	139,458 Added 6.55%	2,267,258 $94.5 Million
Q4 2020 Feb 12, 2021	BUY	$25.81 - $43.62 $2.19 Million - $3.7 Million	84,776 Added 4.15%	2,127,800 $90.9 Million
Q3 2020 Nov 13, 2020	BUY	$25.74 - $29.63 $3.42 Million - $3.93 Million	132,683 Added 6.95%	2,043,024 $53.7 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $436,036 - $719,392	26,833 Added 1.42%	1,910,341 $51.2 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $18,417 - $28,924	-1,325 Reduced 0.07%	1,883,508 $33.9 Million
Q4 2019 Feb 13, 2020	BUY	$14.93 - $19.53 $900,771 - $1.18 Million	60,333 Added 3.31%	1,884,833 $33.4 Million
Q3 2019 Nov 12, 2019	SELL	$15.2 - $17.69 $141,937 - $165,189	-9,338 Reduced 0.51%	1,824,500 $28.3 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $2.74 Million - $3.2 Million	185,483 Added 11.25%	1,833,838 $31.5 Million
Q1 2019 May 14, 2019	BUY	$13.94 - $17.58 $1.78 Million - $2.24 Million	127,698 Added 8.4%	1,648,355 $26.5 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $1.02 Million - $1.43 Million	76,753 Added 5.32%	1,520,657 $22.2 Million
Q3 2018 Nov 13, 2018	BUY	$16.68 - $18.41 $675,256 - $745,292	40,483 Added 2.88%	1,443,904 $26.2 Million
Q2 2018 Aug 14, 2018	BUY	$16.87 - $20.3 $2.18 Million - $2.63 Million	129,403 Added 10.16%	1,403,421 $23.7 Million
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $389,940 - $484,568	22,857 Added 1.83%	1,274,018 $25 Million
Q4 2017 Feb 13, 2018	BUY	$16.75 - $20.8 $1.64 Million - $2.04 Million	98,045 Added 8.5%	1,251,161 $25.3 Million
Q3 2017 Nov 14, 2017	SELL	$11.76 - $17.4 $31,552 - $46,684	-2,683 Reduced 0.23%	1,153,116 $20 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,155,799	1,155,799 $14.8 Million

Others Institutions Holding HALO

# of Institutions

442

Shares Held

122M

Call Options Held

216K

Put Options Held

140K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.24B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Halozyme Therapeutics, Inc. Transaction History